Researchers from Voyager Therapeutics Inc. presented preclinical activity data of VY-1706, a blood-brain barrier (BBB)-penetrant gene therapy comprising an adeno-associated virus serotype 9 capsid ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback